Compare JD.Com Inc (JD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? JD.Com Inc trades at $27.05 (market cap $36.62B), while Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.5× JD.Com Inc's market cap, and JD.Com Inc pays a 3.72% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 85 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| JD | VRTX | |
|---|---|---|
Market Cap | $36.62B | $127.55B |
Volume | 6,571,477 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $557.96 |
52-Week Low | $25.19 | $407.37 |
Typical Hold Time | 85 Days | 120 Days |
Enterprise Value | $19.26B | $121.68B |
Dividend Yield | 3.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com stock trades at $27.03, up 2.0% today, with a bullish technical signal and strong analyst consensus. The company reported revenue of $1.31 trillion in 2025, though net income declined to $19.63 billion. Recent news highlights potential EU approval for its $2.5 billion Ceconomy acquisition, a key strategic move.
The outlook is positive given deep valuation discounts (P/E 17.9, P/S 0.2) and robust cash flow, but risks include revenue pressure and regulatory scrutiny. Analyst price targets average $35.86, implying significant upside from current levels if execution improves.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
